罗格列酮和匹格列酮间无明显差别。
No difference between rosiglitazone and pioglitazone was apparent.
从1999年开始，马来酸罗格列酮和盐酸匹格列酮被批准使用。
Beginning in 1999, rosiglitazone maleate and pioglitazone hydrochloride were approved for use.
罗格列酮和匹格列酮2010年处方量分别为历史最高处方量的7%和47%。
By 2010, new prescriptions for rosiglitazone and pioglitazone were at 7% and 47%, respectively, of peak levels.
来自Lincoff等的研究，重新回顾了来自匹格列酮的一些临床试验的数据。
The study by Lincoff et al. reviewed the data from clinical trials of pioglitazone.
但是，这一发现可能低估了匹格列酮的益处，因为继发于初始事件的继发事件也被减少。
This finding, however, might be an underestimate of the benefit of pioglitazone, since events subsequent to the initial one are also reduced.
在使用匹格列酮的患者中，严重的心力衰竭增加，但是没有引起与之相关的死亡率的增加。
Serious heart failure is increased in patients on pioglitazone, although there is no associated increase in mortality.
服用匹格列酮的病人平均进行了380天的治疗，服用罗格列酮的病人平均进行了369天的治疗。
Patients taking pioglitazone averaged 380 days of medication, and patients taking rosiglitazone averaged 369 days of medication.
让我们先谈一下TZD类罗格列酮和匹格列酮，我想它们均有使人们对其防治糖尿病的兴趣减少的问题。
Let us say that at first the TZDs which is the rosiglitazone and the pioglitazones had problems which I think will decrease the interest yet on the protection of diabetes.
另外，一种用于治疗糖尿病的药物Actos(匹格列酮)也可改善NASH的很多症状，但会导致肥胖。
In addition, Actos (pioglitazone), a drug used to treat diabetes, also improved many features of NASH but was associated with weight gain.
调整潜在的混杂因素后，服用罗格列酮的病人比服用匹格列酮的病人的死亡率高15%，心衰风险高13%。
Adjusting for potential confounding factors, individuals on rosiglitazone had 15% higher rate of death and 13% higher risk of heart failure.
一项新的研究显示患有糖尿病的绝经妇女在服用噻唑烷二酮类药物，包括匹格列酮与罗格列酮时，会增加骨折的危险。
A new study has revealed that postmenopausal women with diabetes taking thiazolidinediones (TZDS), including rosiglitazone and pioglitazone, may be at increased risk for fractures.
结果显示，10年间对7,846例2型糖尿病患者开具了罗格列酮、匹格列酮以及新上市药物处方共计9,178份。
Over the 10-year study period, 7,846 patients with type 2 diabetes had 9,178 new prescriptions for rosiglitazone, pioglitazone, and other agents.
研究者判断，对所有这93个使用罗格列酮而不是匹格列酮的患者来说，每一次意外发生的心血管事件都意味着以后将每年发作一次。
The researchers estimate that, for every 93 patients treated with rosiglitazone rather than pioglitazone, one additional cardiovascular event or death would be predicted to occur annually.
研究者判断，对所有这93个使用罗格列酮而不是匹格列酮的患者来说，每一次意外发生的心血管事件都意味着以后将每年发作一次。
The researchers estimate that, for every 93 patients treated with rosiglitazone rather than pioglitazone, one additional cardiovascular event or death would be predicted to occur annually.
应用推荐